gastric cancer

News

Japan clears first CLDN18.2 drug, Astellas’ Vyloy

Astellas has become the first drugmaker to bring a claudin 18.2 (CLDN18.2) targeted therapy to regulatory approval, getting a green light in Japan for Vyloy as a treatment

News

FDA blocks Astellas’ Claudin cancer drug over manufacturing

Manufacturing problems have scuppered Astellas’ chances of approval in the US this month for zolbetuximab, currently leading the field among Claudin 18.2-targeted drug can

News

Keytruda gets front-line gastric cancer okay in EU

The European Commission has given approval to MSD's Keytruda as a first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

News

FDA grants Priority Review of Astellas’ zolbetuximab BLA

Astellas Pharma Inc has announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review of its zolbetuximab Biologics License Application

Oncology

ASCO 2023 – Mark Reisenauer

As we approach the last of our exclusive coverage of ASCO 2023, editor-in-chief Jonah Comstock speaks with Mark Reisenauer, president of US commercial at Astellas.

News